Parkinson’s and waste removal
An important aspect to keep a cell healthy and functioning correctly is the breakdown and recycling of waste. This process is regulated by lysosomes; however, issues with them are common in neurons of people with Parkinson’s and may help drive cell loss.
What are lysosomes?
Lysosomes are like the bin men of the cell – they handle the breakdown, disposal, and recycling of cellular waste. This includes things like excess proteins and dysfunctional or old cell structures. To achieve this, lysosomes are filled with specialised enzymes– proteins that catalyse (speed-up) chemical reactions. Lysosomes taxi these enzymes around the cell, breaking down waste as they go.
Issues with this waste disposal system are common in the nerve cells (neurons) of people with Parkinson’s and this is thought to contribute to cell loss. Problems that fall under this umbrella include issues with lysosomes, the enzymes they carry, and with transporting enzymes from where they are assembled to the lysosome. Researchers are currently looking at therapies that can address these problems, with the aim to increase neuron survival, therefore slowing Parkinson’s progression.
Why is waste removal important for Parkinson’s?
The removal of cellular waste is essential for a cell’s wellbeing. Problems with the lysosomes themselves is often seen in Parkinson’s, which can impact other drivers of Parkinson’s progression such as the accumulation of excess proteins and dysfunctional structures. More specifically, waste disposal problems can lead to the build-up of alpha-synuclein, as well as mitochondrial dysfunction.
Alpha-synuclein
Build-ups of dysfunctional copies of the protein alpha-synuclein are a hallmark and driver of Parkinson’s. This version of alpha-synuclein is sticky, clumping together to form Lewy bodies. Lewy bodies interfere with other cell processes, eventually leading to cell death if not cleared.
Learn more about alpha-synuclein and Parkinson’s.
Reduced lysosomal activity may contribute to neuron’s inability to mitigate these build-ups. Additionally, there is evidence to suggest that alpha-synuclein and Lewy bodies may interfere with the transport of enzymes to the lysosome, further reducing lysosomal activity.
Mitochondrial dysfunction
Mitochondria are like battery packs for the cell, creating and providing all the energy cells need to function. Over time, however, these mitochondria become less efficient and eventually need to be recycled in a process called mitophagy. Besides not being able to meet the energy demands of the cell, dysfunctional mitochondria can also lead to an overproduction of toxic molecules called reactive oxygen species, which in excess can trigger cell death.
Learn more about mitochondrial dysfunction.
Lysosomes are integral to this process as they are recruited to breakdown mitochondria. Therefore, reduced lysosomal activity or issues with recruiting these lysosomes may contribute to the accumulation of dysfunctional mitochondria.
How can genes play a role?
Genes are segments of our DNA (our genetic/hereditary information) that contain the instructions for building proteins and for directing cell activity. Mutations, or small changes in this genetic code, can muddy these instructions, leading to cells building less effective or dysfunctional proteins.
There are several genetic variations associated with a higher risk of developing Parkinson’s. The most common of these are variations to the GBA1 gene, which provides the instructions for building the lysosomal enzyme glucocerebrosidase (GCase). GCase activity is thought to decrease naturally with age but may be even lower in people with GBA1 mutations, affecting the cell’s ability to breakdown waste. Researchers believe therapies that increase GCase activity, such as ambroxol, could therefore have a protective effect on neurons.
A new potential biomarker for Parkinson’s
Researchers at Duke University have recently presented data on a new potential biomarker for Parkinson’s.
New research exploring ethnic diversity in Parkinson’s
A recent study from the Global Parkinson’s Genetic Program found a novel genetic risk factor for Parkinson’s in people of African ancestry. This finding once again brings to light…
A new case for GCase
Low levels of a protein called GCase is associated with an increased risk of developing Parkinson’s. New understandings of the role of GCase could help to further explain other…
New clinical trials targeting the LRRK2 gene
LRRK2 is a protein that becomes hyperactive in some people with Parkinson’s, and this is believed to be involved in the progression of their Parkinson’s.
Research Update Meeting Spring 2023 – recorded to watch again
Our popular and much-awaited research update meeting brought together two leading clinicians to report on their individual area of expertise for Parkinson’s. It’s available to watch again!
The role of faulty cell protein in Parkinson’s
A process called m6A mRNA methylation is reduced in people with Parkinson’s. Research is underway to develop drugs that can improve this protein production process.
Phase 3 clinical trial of ambroxol for Parkinson’s confirmed
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
GCase and Parkinson’s: a new perspective
Recently researchers have provided new insights into how small defects in a region of DNA called the GBA gene could be affecting cell biology leading to Parkinson’s.
PD Frontline
As research has expanded in the area of Parkinson’s genetics, researchers have been able to uncover a number of genes which have been linked to an increased risk of…
Something ‘LRRK -ing’ in the data
Over recent years, researchers have been identifying genetic variations associated with an increased risk of developing Parkinson’s. A recent study has thrown further light on the connection between certain…
Important phase 1 trial results for LRRK2 inhibitor drug
This week the biotech company Denali Therapeutics announced the results of a phase 1 clinical trial of their LRRK2 inhibitor drug called ‘DNL151’. Their findings have interesting implications for…
Results of the MOVES-PD trial announced
MOVES-PD is a global phase 2 study to assess the efficacy and safety of the drug venglustat in Parkinson’s patients who have a GBA-1 gene mutation. Sanofi designed the…
Ambroxol – new real-world data
Ambroxol is a cough medication that Cure Parkinson’s is repurposing for potential use in treating Parkinson’s, and recently published data provides further support for this pioneering new study.
The AIM-PD trial (ambroxol)
Supported and funded by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly. Phase 2 of the ‘AIM-PD’…
The epigenetics of Parkinson’s.
Researchers at the Van Andel Institute in Grand Rapids (Michigan) have identified a “master regulator” gene switch that may protect the brain from neurodegenerative processes associated with Parkinson’s.
DENALI and Biogen team up against LRRK2
The biotech company Denali have announced that they have signed a collaborative deal with the pharmaceutical company Biogen.
A greater role for the parkinson’s GBA gene protein?
There is a great deal of variability between each person affected by Parkinson’s. Better knowledge of these variables could not only provide insights into the underlying biology of…
The STEADY-PD Trial Results
Cure Parkinson’s recently approved funding for a project with Associate Professor Antony Cooper, Garvan Institute, Sydney. The project aimed to determine if there is a group of people with…
Ambroxol in Parkinson’s: results of phase 2 trial published
Cure Parkinson’s, in partnership with Van Andel Institute and the John Black Charitable Foundation, is proud to announce the publication of the results of the phase 2 clinical trial…
Keeping Pace with LRRK2 and GCase
There are a number of genetic variations that can increase one’s risk of developing Parkinson’s. Two of the most common genetic variations or mutations occur in regions of human…
GP2: global Parkinson’s genetics program
In almost every cell of a human body, genetic material or DNA is translated into proteins, referred to as genes. These genes provide the instructions for making and maintaining…
Ambroxol: Further validation for potential in Parkinson’s
Small variations in DNA are associated with approximately 1 in 5 of Parkinson’s cases. One of the most common genetic risk factors of developing Parkinson’s occurs in a region of…